Who Are the Core Customers in 23andMe Company's Target Market?

These are health-conscious consumers with high disposable income, often aged 30 – 55, who purchase health reports and the 23andMe plus subscription; they drive recurring revenue and higher lifetime value.

Direct-to-consumer DNA buyers focused on genealogy use DNA Relatives and ethnicity reports to build family trees; this segment fuels one-time kit sales and social referrals.

23andMe serves consumers (health and ancestry test customers) and institutional buyers; enterprise deals with pharma – such as historical collaborations with GSK – monetize the research-consented dataset.

Revenue drivers are consumer health reports and the 23andMe plus subscription plus B2B data partnerships; the company reports research consent rates near 80%, which underpins pharma licensing value and clinical discovery.

The United States accounts for over 70 percent of 23andMe total revenue in 2025, reflecting concentrated demand among health-conscious consumers and direct-to-consumer DNA buyers seeking ancestry and health test customers; high out-of-pocket healthcare costs push consumers toward self-directed preventative care.

The United Kingdom and Canada show rising demand as genetic literacy climbs among middle-class households; these markets represent the primary international expansion targets for 23andMe customer segments outside North America.

Digital channels – 23andMe direct-to-consumer platform and large marketplaces like Amazon – remain the dominant acquisition paths, accounting for the bulk of transactional intent to buy 23andMe ancestry kit online and repeat buyers; digital sales contribute the largest share of revenue and customer reach.

By 2025, telehealth integration via Lemonaid Health increased genetics-informed primary care uptake, boosting pharmacogenetics report interest and conversions; integrated health environments are the fastest-growing channel for health-conscious consumers buying 23andMe health reports.

23andMe adds customers by promoting the 23andMe plus subscription in 2025 to convert ancestry and health test customers into recurring buyers, targeting millennials and Gen Z with bundled ancestry-health reports, and launching targeted clinical trial recruitment services using its database to attract consumers interested in pharmacogenetics reports and clinical participation. Recent disclosures show active users near 11 million and database scale used to market trial recruitment to biopharma partners.

Retention rests on continuous report updates in the subscription model and perceived value from contributing to therapeutics research; participants in studies for conditions like Crohn's and lupus report higher loyalty. Management guidance for 2026 emphasizes reaching a subscription attach rate of 15 – 20% of active users to offset high drug development costs and stabilize revenues as kit sales plateau.

Repeat purchases and referrals are driven by periodic report refreshes, family-building use cases, and trust in data-driven health insights; customers comparing 23andMe vs AncestryDNA often repurchase for upgraded health modules. Clinical trial recruitment and therapeutics pipelines create ecosystem stickiness and a path from transactional kit buyers to long-term subscribers.

The primary growth lever is the 23andMe plus subscription converting direct-to-consumer DNA buyers into recurring revenue; achieving a 15 – 20% attach rate of the ~11 million active user base is the make-or-break metric for sustaining operations while drug R&D continues. For more context on the business model and revenue lines, see How 23andMe Company Works and Makes Money.